$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017 [Report Updated: 28-02-2017]

Published by Global Markets Direct: 28 Feb 2017 | 47392 | In Stock

Introduction

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.

Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 7, 1, 19, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017 [Report Updated: 28-02-2017]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment

    Assessment by Target

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development

    A1M Pharma AB

    Alloksys Life Sciences BV

    Am-Pharma BV

    Angion Biomedica Corp

    Atox Bio Ltd

    Cellmid Ltd

    Complexa Inc

    DiaMedica Therapeutics Inc

    DURECT Corp

    Evotec AG

    Exponential Biotherapies Inc

    F. Hoffmann-La Roche Ltd

    G1 Therapeutics Inc

    Kringle Pharma Inc

    Mitotech SA

    NephroGenex Inc

    NeuroVive Pharmaceutical AB

    Nyken BV

    ProMetic Life Sciences Inc

    Quark Pharmaceuticals Inc

    Regulus Therapeutics Inc

    SBI Pharmaceuticals Co Ltd

    Spherium Biomed SL

    STATegics Inc

    Stealth BioTherapeutics Inc

    Thrasos Therapeutics Inc

    Torrent Pharmaceuticals Ltd

    Xigen SA

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles

    (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    A1M-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AB-103 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Antisense RNAi Oligonucleotides for Acute Kidney Injury and Chronic Kidney Disease - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BB-3 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    brimapitide - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CAB-101 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CXA-10 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DM-199 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Drug for Kidney Diseases - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    DUR-928 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    EA-230 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    elamipretide - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KP-100IT - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MG-53 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NOXD-21 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NVP-019 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    NYK-1341 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    PBI-4419 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Plastomitin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Pyridoxamine Dihydrochloride - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    QPI-1002 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    R-190 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Human Alkaline Phosphatase - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Human Alkaline Phosphatase Replacement for Acute Renal Failure, Hypophosphatasia, Sepsis and Ulcerative Colitis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RLS-003 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RMC-035 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RO-6839328 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit HDAC for Acute Kidney Injury - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SP-15016 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    STSE-15 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    THR-184 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TRC-160334 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Vanadis-03 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products

    Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones

    Featured News & Press Releases

    Feb 10, 2017: A1M Pharma has successfully conducted large scale manufacturing of the active substance in ROSGard and initiates GLP toxicology studies

    Jan 31, 2017: Angion Biomedica Phase 2 “GUARD” Clinical Trial of BB3 in Acute Kidney Injury (AKI) Underway; Complements Ongoing Phase 3 Study in Renal Transplant Recipients with Delayed Graft Function

    Jan 30, 2017: DURECT Announces Update on DUR-928 Development Program

    Dec 20, 2016: Silence Therapeutics Announces Quark Arbitration Resolution

    Dec 09, 2016: ROSGard shows renal protective effect during radiation therapy

    Nov 07, 2016: Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

    Sep 19, 2016: Quark Pharmaceuticals to provide an update on kidney transplant drug QPI-1002

    Sep 13, 2016: A1M Pharma selects kidney protection in connection with cancer treatment as their first indication within acute kidney injury

    May 10, 2016: AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial

    Apr 26, 2016: AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury

    Apr 19, 2016: AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design”

    Mar 14, 2016: Quark Pharmaceuticals Doses First Patient In Two Pivotal Clinical Studies of RNAi-Based Therapeutic QPI-1002

    Feb 29, 2016: Thrasos Announces Promising Results for Phase II THR-184 Dose Ranging Clinical Study for the Prevention of Acute Kidney Injury (AKI)

    Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928

    Dec 14, 2015: NephroGenex Announces FDA Clearance Of IND Application For Clinical Study Of Intravenous Pyridorin In The Treatment Of Acute Kidney Injury

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

47392 | GMDHC8976IDB

Number of Pages

134

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016
Acute Renal Failure (ARF) (Acute Kidney Injury) Global Clinical Trials Review, H1, 2016SummaryGlobal...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Pain Global Clinical Trials Review, H1, 2016
Acute Pain Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “Acute ...
20 Apr 2016 by Global Data USD $2,500 More Info
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016
Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016SummaryGlobalData's clini...
29 Feb 2016 by Global Data USD $2,500 More Info
Acute Stress Disorder Global Clinical Trials Review, H2, 2015
Acute Stress Disorder Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial repo...
16 Dec 2015 by Global Data USD $2,500 More Info
Acute Injury Global Clinical Trials Review, H2, 2015
Acute Injury Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report, “Acut...
09 Dec 2015 by Global Data USD $2,500 More Info
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015
Acute Respiratory Failure Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial ...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015
Acute and Sub-Acute Bursitis Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical tri...
25 Nov 2015 by Global Data USD $2,500 More Info
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015
Altitude Sickness (Acute mountain sickness) Global Clinical Trials Review, H2, 2015SummaryGlobalData...
25 Nov 2015 by Global Data USD $2,500 More Info
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015
Acute Upper Respiratory Tract Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's ...
30 Oct 2015 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2017 [Report Updated: 28-02-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data